Observation of 42 Cases of Therapeutic Effects of Liuwei Wuling Tablet in Treatment of Hepatitis B with Hepatic Fibrosis

LI Guang-ming; ZHOU Feng-rui; LIU Jun-hua; LING Yu; CHEN Min

doi:10.11653/syfj2013210276

您当前的位置：

首页 >

文章列表页 >

Observation of 42 Cases of Therapeutic Effects of Liuwei Wuling Tablet in Treatment of Hepatitis B with Hepatic Fibrosis

更新时间：2024-01-04

- Observation of 42 Cases of Therapeutic Effects of Liuwei Wuling Tablet in Treatment of Hepatitis B with Hepatic Fibrosis
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 19, Issue 21, Pages: 276-279(2013)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.11653/syfj2013210276
  CLC：
- Published：2013
- 稿件说明：
移动端阅览
LI Guang-ming, ZHOU Feng-rui, LIU Jun-hua, et al. Observation of 42 Cases of Therapeutic Effects of Liuwei Wuling Tablet in Treatment of Hepatitis B with Hepatic Fibrosis[J]. Chinese journal of experimental traditional medical formulae, 2013, 19(21): 276-279.
DOI：

LI Guang-ming, ZHOU Feng-rui, LIU Jun-hua, et al. Observation of 42 Cases of Therapeutic Effects of Liuwei Wuling Tablet in Treatment of Hepatitis B with Hepatic Fibrosis[J]. Chinese journal of experimental traditional medical formulae, 2013, 19(21): 276-279. DOI： 10.11653/syfj2013210276.

摘要

目的: 探讨六味五灵片治疗乙型肝炎肝纤维化的临床疗效及对单胺氧化酶(MAO)和转化生长因子-β1(TGF-β1)的影响。方法: 84例患者随机按数字法分为观察组和对照组各42例。两组采用常规治疗(如维生素、保肝类药物)

并口服恩替卡韦

0.5 mg/次

1次/d

观察组加服六味五灵片

1.5 g/次

3次/d。两组疗程均为24周。进行治疗前后肝功能、肝纤维化指标、MAO及TGF-β1检测

B超检查肝脾。结果: 治疗后观察组总有效率90.5%

优于对照组的61.9% (P<0.01);治疗后观察组丙氨酸转氨酶(ALT)

天冬氨酸氨基转氨酶(AST)及总胆红素(TBIL)水平较对照组低(P<0.01);观察组血清透明质酸(HA)、层黏连蛋白(LN)、Ⅲ型前胶原(PCⅢ)及Ⅳ型胶原(IV-C)水平均低于对照组(P<0.01);治疗后两组血清MAO

TGF-β1水平均明显下降

观察下降更为显著(P<0.01);治疗后观察组脾厚低于对照组(P<0.05)。结论: 六味五灵片能通过抑制乙型肝炎肝纤维化患者血清MAO和TGF-β1表达来抑制肝星状细胞的活化

从而阻止肝纤维化的发展。

Abstract

Objective: The purpose is to study the clinical curative effect of Liuwei Wuling tablet in the treatment of liver fibrosis in hepatitis B and its influences on the determination of monoamine oxidase (MAO) and transforming growth factor β1(TGF-β1). Method: Eighty-four cases of patients were randomly divided into observation group (42 cases) and control group (42 cases). Patients in both groups all took the conventional treatment (eg

vitamins

liver-protect drugs) and the entecavir by oral

0.5 mg/time

1 time/day. The patients in observation group took Liuwei Wuling tablet

1.5 g/time

3 times/day. The treatment course of two groups was 24 weeks. The liver function

liver fibrosis indexes

MAO and TGF-β1 were tested before and after the treatment

examining liver and spleen by ultrasound B. Result: After the treatment

the total effective rate of observation group was 90.5%

Better than the control group 61.9% in the control group(P<0.01). The level of Alanine aminotransferase(ALT)

aspartate transaminase(AST) and total bilirubin(TBIL) of observation group was lower than those of control group (P<0.01). Also

the serum hyaluronic acid(HA)

laminin(LN)

procollagen type Ⅲ(PCⅢ) and collagen type Ⅳ(Ⅳ-C) level of observation group were lower than the control group (P<0.01). The serum MAO and TGF-β1 level of the two groups were obviously decreased and the decline in observed group was more significantly (P<0.01). The spleen thickness of patients in observation group was lower than the control group after treatment (P<0.05). Conclusion: Liuwei Wuling tablet can inhibit the expression of serum MAO and TGF-β1 of the hepatitis B liver fibrosis patients

further to inhibit the activation of hepatic stellate cells

preventing the development of liver fibrosis. The clinical curative effect of Liuwei Wuling tablet is significant and worthy of promotion.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of Kangxian'gan Decoction in Treating 54 Cases with Liver Fibrosis Caused by Chronic Hepatitis B

Ganshuang Granule Alleviates Early Liver Fibrosis （S1 and S2） in Chronic Hepatitis B with Liver Depression Spleen Deficiency and Blood Stasis Syndrome

Effects and Mechanism of Supplemental Sini San on Hepatic Fibrosis in Rats

Mechanism and Combination Therapy of Berberine in Treatment of Nonalcoholic Fatty liver Disease：A Review

Related Author

HAN Man-zhu

WANG Fen

LI Li

LU Bi-xue

LUO Ling-jie

Li LIU

Jing YANG

Zong-yun LI

Related Institution

School of Pharmacy， North China University of Science and Technology

Harrison International Peace hospital

Department of Physiology,Henan University of Traditional Chinese Medicine

Henan General Hospital

The First Affiliated Hospital of Henan University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰